GLP-1 Drugs: Beyond Diabetes – Cardiovascular Benefits and Rising Legal Concerns

Originally developed to manage type 2 diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists—including medications like Ozempic, Wegovy, and Mounjaro—have gained widespread attention for their effectiveness in weight loss. However, recent research highlights a potentially significant additional benefit: cardiovascular protection. Alongside these advancements, a growing number of lawsuits allege serious side effects associated with these drugs, raising concerns about patient safety and manufacturer responsibility.

How GLP-1 Drugs Work

GLP-1 medications mimic the effects of the naturally occurring GLP-1 hormone, which plays a crucial role in regulating blood sugar, appetite, and digestion. These drugs work by stimulating insulin release when blood sugar levels are high, slowing down gastric emptying to promote feelings of fullness, and reducing appetite. WebMD explains that GLP-1 agonists act like a substance the body naturally produces to lower blood sugar.

Cardiovascular Benefits: A Growing Body of Evidence

Emerging research suggests that GLP-1 receptor agonists offer substantial cardiovascular benefits beyond their glucose-lowering effects. Studies indicate these drugs can reduce the risk of major adverse cardiovascular events (MACE), such as heart attack, stroke, and cardiovascular death. The drugs appear to achieve this by improving several cardiovascular risk factors, including blood pressure, cholesterol levels, and inflammation. Recent findings suggest these medications could even prevent fatal complications from heart attacks. USA Today reports on a UK study finding weight-loss drugs could prevent fatal complications from heart attacks.

GLP-1 Drugs: A Comparison

Several GLP-1 agonists are currently available, each with slightly different characteristics. Some of the most commonly prescribed include:

• Ozempic: Primarily indicated for type 2 diabetes, but also used off-label for weight loss.
• Wegovy: Specifically approved for chronic weight management.
• Mounjaro: Approved for both type 2 diabetes and weight loss.
• Zepbound: A newer agent also approved for weight loss.
• Trulicity & Victoza: Established GLP-1 agonists for diabetes management. GLP-1.com

While all these medications share a common mechanism of action, they differ in dosage, administration (e.g., weekly injection), and potential side effects. GoodRx provides a detailed comparison of various GLP-1 agonists.

Legal Concerns and Reported Side Effects

Despite their benefits, GLP-1 receptor agonists have been linked to a range of adverse effects, prompting a surge in lawsuits. As of January 28, 2026, over 4,400 lawsuits have been filed alleging that drug manufacturers failed to adequately warn patients about the risk of severe injuries. USA Today details several cases, including reports of vision loss, brain dysfunction, and even colon rupture.

Reported side effects include nausea, vomiting, diarrhea, and constipation. More serious, though less common, complications have also been reported, as highlighted in the ongoing litigation.

Who is Using GLP-1 Drugs?

The utilize of GLP-1 drugs has dramatically increased in recent years. Approximately 12% of American adults—over 31 million people—are currently using a GLP-1 medication, primarily for weight management, diabetes control, and reducing the risk of heart disease. USA Today cites estimates from the KFF health policy organization.

Looking Ahead

GLP-1 receptor agonists represent a significant advancement in the treatment of both diabetes and obesity, with emerging evidence suggesting substantial cardiovascular benefits. However, the rising number of lawsuits underscores the importance of careful patient selection, thorough risk-benefit assessment, and transparent communication about potential side effects. Continued research and post-market surveillance are crucial to fully understand the long-term effects of these medications and ensure patient safety.